Curaleaf Holdings, Inc., a leading North American cannabis consumer products provider, announced on May 26 that its board of directors has approved a 1-for-3 reverse stock split, expected to take effect around June 5, 2026. This strategic move aims to meet the share price requirements of major U.S. stock exchanges, positioning the company for a potential uplist from the over-the-counter market to Nasdaq or the New York Stock Exchange.
According to the announcement, Curaleaf currently has approximately 698.7 million subordinate voting shares outstanding. Following the consolidation, this number will be reduced to about 232.9 million shares. The company will not issue fractional shares as part of the split; instead, fractional share entitlements for shareholders will be rounded up to the nearest whole share. Registered shareholders will receive exchange letters by mail, while investors holding shares through brokers do not need to take any action.
Boris Jordan, Chairman and CEO of Curaleaf, stated, "The rescheduling of medical cannabis has created a potential pathway to uplist to a major U.S. exchange, and we are more prepared than ever. With the conclusion of the full cannabis rescheduling hearings in July and forthcoming guidance from the U.S. Treasury supporting industry normalization, we believe the regulatory and tax frameworks will become much clearer soon. We are preparing to act swiftly and decisively when the opportunity arises."
Fundamentally, Curaleaf's uplisting preparations coincide with a historic turning point in its financial performance. According to its first-quarter earnings report released on May 5, 2026, the company achieved net revenue of $324.2 million, a 6% year-over-year increase that exceeded market expectations. International revenue grew 35% to $47 million, driven by strong performance in Germany and the U.K. Notably, the company reported net income from continuing operations of $70.1 million, reversing a trend of losses over the previous five consecutive quarters. Gross margin stood at 49%, with adjusted EBITDA reaching $63.4 million, though international expansion negatively impacted margins by 170 basis points.
The reverse stock split is being pursued against the backdrop of a historic shift in U.S. federal cannabis policy. On April 30, the U.S. Drug Enforcement Administration formally initiated the administrative process to reclassify cannabis from Schedule I to Schedule III under the Controlled Substances Act, with a 60-day public comment period ending in July. Analysts suggest that rescheduling would help operators like Curaleaf reduce their tax burden under IRS Section 280E, which prohibits businesses selling controlled substances from deducting ordinary business expenses, thereby significantly improving profitability. Furthermore, on May 20, the U.S. Treasury's Office of the Comptroller of the Currency issued guidance clarifying that banks can serve legal cannabis-related businesses, further removing barriers to industry normalization.
Simultaneously, Curaleaf is advancing its transformation strategy across multiple dimensions. In the first quarter, operating free cash flow reached $21.3 million, with cash and cash equivalents totaling $106.1 million and outstanding debt at $565 million. The company has secured a commitment for $500 million in private senior secured notes to refinance its $475 million notes maturing in December 2026. Regarding retail expansion, Curaleaf operates over 160 dispensaries in the U.S., with recent openings in Jacksonville Beach and Fernandina Beach, Florida, bringing the state's total to 73 locations. Analysts project Curaleaf's revenue target for 2029 to be $1.6 billion, with a profit target of $117.4 million. Uplisting to a major exchange is expected to enhance the company's liquidity, broaden institutional investor participation, and further legitimize and increase recognition of the cannabis industry in public markets.
Comments